Health & Medicine

STAT+: Pharmalittle: We're reading about an AstraZeneca setback, falling U.S. drug prices, and more

33 sec read16 views0 listens

AstraZeneca has discontinued a late-stage trial for its experimental lung cancer drug volrustomig due to poor performance, adding to concerns about the company's development pipeline. Meanwhile, prescription drug prices in the U.S. have fallen by 3.1% year-over-year, marking the steepest decline in over six decades, partly attributed to policy changes and negotiations under the Inflation Reduction Act.

This trend is significant for developers and tech professionals as it signals a shift towards more cost-effective healthcare solutions and increased regulatory scrutiny on drug efficacy and pricing.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & PharmaMar 932 sec read

STAT+: Pharmalot: We're reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more

The FDA is facing criticism for significantly reducing advisory committee meetings under Commissioner Marty Makary's leadership, which has led to increased regulatory uncertainty and political involvement in scientific decisions. Additionally, the FD...

Ali Nemati

Health & Medicine2 days ago29 sec read

STAT+: Pharmalittle: We're reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more

Regeneron Pharmaceuticals has received U.S. regulatory approval for Pasatru, a drug aimed at treating fibrodysplasia ossificans progressiva (FOP), a rare disease causing abnormal bone growth. Separately, Ultragenyx Pharmaceutical’s gene therapy Gengl...

Ali Nemati

Health & Medicine3 days ago25 sec read

STAT+: Pharmalittle: We're reading about an FDA commish nominee, mRNA cancer vaccine results, and more

President Trump is expected to nominate Heidi Overton, a key health policy advisor in his administration, as the next FDA commissioner. Additionally, a late-stage clinical trial shows that a personalized mRNA cancer vaccine, when combined with existi...

Ali Nemati